Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zizao Yangrong is a traditional Chinese medicine (TCM) formula primarily used in the form of granules or decoction. It is designed to treat skin xerosis (dryness) induced by epidermal growth factor receptor inhibitors (EGFRIs), which are targeted anti-cancer drugs. Clinical studies have shown that Zizao Yangrong can effectively alleviate EGFRI-related xerosis and improve patients' quality of life without significant adverse effects. The mechanism of action involves modulation of pathways related to skin barrier function and inflammation, though the precise molecular targets remain under investigation[1][2][3]. The formula is typically used as an adjunct therapy alongside standard dermatologic treatments such as vitamin E ointment for cancer patients experiencing cutaneous side effects from EGFRIs[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zizao Yangrong.